CARs to the rescue: rare aggressive lymphoma gets a power up.
作者信息
Kamdar Manali
机构信息
Division of Hematology and Bone Marrow Transplantation, University of Colorado, Aurora, CO.
出版信息
Blood Adv. 2024 Oct 22;8(20):5342-5343. doi: 10.1182/bloodadvances.2024014118.
Abstract
摘要
相似文献
1
CARs to the rescue: rare aggressive lymphoma gets a power up.
Blood Adv. 2024 Oct 22;8(20):5342-5343. doi: 10.1182/bloodadvances.2024014118.
2
Current landscape for chimeric antigen receptor T cells in lymphomas.
Curr Opin Hematol. 2019 Nov;26(6):421-426. doi: 10.1097/MOH.0000000000000544.
3
Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
Curr Treat Options Oncol. 2022 Feb;23(2):171-187. doi: 10.1007/s11864-021-00920-6. Epub 2022 Feb 25.
4
FDA investigates risk of secondary lymphomas after CAR-T immunotherapy.
Lancet Oncol. 2024 Jan;25(1):21. doi: 10.1016/S1470-2045(23)00631-9. Epub 2023 Dec 7.
5
CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.
Leuk Lymphoma. 2019 May;60(5):1346-1348. doi: 10.1080/10428194.2018.1533132. Epub 2019 Jan 16.
6
A review of chimeric antigen receptor T-cells in lymphoma.
Expert Rev Hematol. 2019 Jul;12(7):551-561. doi: 10.1080/17474086.2019.1629901. Epub 2019 Jun 19.
7
Cellular therapy in lymphoma.
Hematol Oncol. 2024 Nov;42(6):e3200. doi: 10.1002/hon.3200. Epub 2023 Jun 29.
8
Perceived Cognitive Changes following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?
Transplant Cell Ther. 2023 Jan;29(1):64. doi: 10.1016/j.jtct.2022.09.008. Epub 2022 Sep 21.
9
Response to: Perceived Cognitive Changes Following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?
Transplant Cell Ther. 2023 Jan;29(1):65. doi: 10.1016/j.jtct.2022.09.019. Epub 2022 Sep 27.
10
Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients.
BMC Cancer. 2023 Oct 23;23(1):1019. doi: 10.1186/s12885-023-11536-4.
本文引用的文献
1
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma.
Blood Adv. 2024 Oct 22;8(20):5290-5296. doi: 10.1182/bloodadvances.2024013863.
2
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol. 2021 Oct;22(10):1403-1415. doi: 10.1016/S1470-2045(21)00375-2. Epub 2021 Sep 10.
3
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
Blood. 2021 Jun 17;137(24):3454-3459. doi: 10.1182/blood.2020009148.
4
Immune escape mechanisms for TCRLBCL.
Blood. 2021 Mar 11;137(10):1274-1276. doi: 10.1182/blood.2020008766.
5
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
6
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
Zotero 插件